Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder.

PURPOSE The primary aim of this study was to assess the range of attitudes towards antipsychotic treatment at hospital discharge in patients with schizophrenia and bipolar disorder. The secondary aim was to analyze the relationship between patients' attitudes and sociodemographic and clinical parameters. PATIENTS AND METHODS A cross-sectional study with a sample of patients admitted due to acute exacerbation of schizophrenia or a manic episode was conducted. Attitude towards pharmacological treatment at discharge was assessed with the 10-item Drug Attitude Inventory (DAI-10). Logistic regression was used to determine significant variables associated with attitude to medication. RESULTS Eighty-six patients were included in the study. The mean age was 43.1 years (standard deviation [SD] 12.1), and 55.8% were males. Twenty-six percent of the patients presented a negative attitude towards antipsychotic treatment (mean DAI-10 score of -4.7, SD 2.7). Most of them had a diagnosis of schizophrenia. Multivariate analysis showed that poor insight into illness and a greater number of previous acute episodes was significantly associated with a negative attitude towards medication at discharge (odds ratio 1.68 and 1.18, respectively). CONCLUSION Insight and clinical stability prior to admission were related to patients' attitude towards antipsychotic treatment at hospital discharge among patients with schizophrenia and bipolar disorder. The identification of factors related to the attitude towards medication would offer an improved opportunity for clinicians to select patients eligible for prophylactic adherence-focused interventions.

[1]  E. Lindström,et al.  DAI-10 is as good as DAI-30 in schizophrenia , 2012, European Neuropsychopharmacology.

[2]  I. Gasquet,et al.  Determinants of treatment satisfaction of schizophrenia patients: Results from the ESPASS study , 2012, Schizophrenia Research.

[3]  Moon-Soo Lee,et al.  Symptom severity and attitudes toward medication: Impacts on adherence in outpatients with schizophrenia , 2012, Schizophrenia Research.

[4]  J. Maurino,et al.  The subjective well-being under neuroleptic scale – short version (SWN-K) and the SF-36 health survey as quality of life measures in patients with schizophrenia , 2012, Patient preference and adherence.

[5]  R. Porter,et al.  Effectiveness of interventions to improve medication adherence in bipolar disorder , 2012, The Australian and New Zealand journal of psychiatry.

[6]  M. Wirtz,et al.  Do Patients With Schizophrenia Distinguish Between Attitudes Toward Antipsychotic Medication and Pharmacotherapy in General?: Validation of the Beliefs About Medication Questionnaire , 2012, The Journal of nervous and mental disease.

[7]  D. Linszen,et al.  Interventions to improve adherence to antipsychotic medication in patients with schizophrenia–A review of the past decade , 2012, European Psychiatry.

[8]  B. Kleim,et al.  Are we addressing the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication , 2011, Schizophrenia Research.

[9]  J. Maurino,et al.  Factors Associated with the Effectiveness of a Telephone-Based Nursing Strategy for Enhancing Medication Adherence in Schizophrenia , 2011, Clinical practice and epidemiology in mental health : CP & EMH.

[10]  D. Goff,et al.  Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. , 2010, The Journal of clinical psychiatry.

[11]  L. Boyer,et al.  Factors Associated with Medication Non-Adherence in Patients Suffering from Schizophrenia: A Cross-Sectional Study in a Universal Coverage Health-Care System , 2010 .

[12]  P. Feldman,et al.  Patient perspectives on antipsychotic treatments and their association with clinical outcomes , 2010, Patient preference and adherence.

[13]  J. Haro,et al.  Assessment of Medication Adherence in a Cohort of Patients with Bipolar Disorder , 2010, Pharmacopsychiatry.

[14]  H. Möller,et al.  Attitude towards adherence in patients with schizophrenia at discharge. , 2009, Journal of psychiatric research.

[15]  V. Agyapong,et al.  Sources of Patients' Knowledge of the Adverse Effects of Psychotropic Medication and the Perceived Influence of Adverse Effects on Compliance Among Service Users Attending Community Mental Health Services , 2009, Journal of clinical psychopharmacology.

[16]  P. Stratta,et al.  Attitudes toward medication and the clinical variables in schizophrenia: Structural equation models , 2009, Patient preference and adherence.

[17]  P. Weiden,et al.  The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. , 2009, The Journal of clinical psychiatry.

[18]  G. Dimaggio,et al.  Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches , 2009, Expert review of neurotherapeutics.

[19]  J. Lieberman,et al.  Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. , 2009, Schizophrenia bulletin.

[20]  W. Dubin,et al.  Medication Adherence: A Review of the Literature and Implications for Clinical Practice , 2009, Journal of psychiatric practice.

[21]  K. Rajagopalan,et al.  Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. , 2008, Clinical therapeutics.

[22]  G. Kemmler,et al.  Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow‐up study in patients with schizophrenia , 2007, Acta psychiatrica Scandinavica.

[23]  M. Rupnow,et al.  Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial , 2006, BMC psychiatry.

[24]  J. Sanjuán,et al.  [Subjective experience with antipsychotics: quantitative evaluation]. , 2006, Actas espanolas de psiquiatria.

[25]  K. Maeda,et al.  Subjective response to neuroleptics: The effect of a questionnaire about neuroleptic side effects , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[26]  M. Swartz,et al.  Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. , 2006, The Journal of clinical psychiatry.

[27]  A. Lippman.  Adherence to medication. , 2005, The New England journal of medicine.

[28]  C. Ko,et al.  Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: Prospective study , 2005, Psychiatry and clinical neurosciences.

[29]  R. Bentall,et al.  Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. , 2005, Archives of general psychiatry.

[30]  M. Lambert,et al.  Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence , 2004, European Psychiatry.

[31]  D. Goff,et al.  Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. , 2004, The Journal of clinical psychiatry.

[32]  W. Fleischhacker,et al.  Factors influencing compliance in schizophrenia patients. , 2003, The Journal of clinical psychiatry.

[33]  Jan Scott,et al.  Nonadherence with mood stabilizers: prevalence and predictors. , 2002, The Journal of clinical psychiatry.

[34]  J. Sacristán,et al.  Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study) , 2001, BMC psychiatry.

[35]  T. Burke,et al.  Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis , 2001, European Psychiatry.

[36]  Jan Scott,et al.  Predicting medication adherence in severe mental disorders , 2000, Acta psychiatrica Scandinavica.

[37]  M. Slade,et al.  A self‐report Insight Scale for psychosis: reliability, validity and sensitivity to change , 1994, Acta psychiatrica Scandinavica.

[38]  J. Gorman,et al.  Assessment of insight in psychosis. , 1993, The American journal of psychiatry.

[39]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[40]  T. Hogan,et al.  A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity , 1983, Psychological Medicine.

[41]  Christian R. Dolder,et al.  Antipsychotic medication adherence: is there a difference between typical and atypical agents? , 2002, The American journal of psychiatry.

[42]  P. Weiden,et al.  Rating of medication influences (ROMI) scale in schizophrenia. , 1994, Schizophrenia bulletin.

[43]  A. Awad.  Subjective response to neuroleptics in schizophrenia. , 1993, Schizophrenia bulletin.

[44]  Awad Ag.  Subjective Response to Neuroleptics in Schizophrenia , 1993 .